SEC filings and other documents

DT-216 demonstrated robust efficacy signals in Friedreich ataxia, with pivotal data due Q1 2027.

Positive RESTORE-FA data and strong cash position support ongoing clinical progress.

Early clinical data in Friedreich's ataxia support rapid advancement to registrational studies.

GeneTACⓇ programs show strong clinical progress and are funded into 2029.

DT-216 delivers rapid, significant frataxin increases and clinical benefit in FA patients.

RESTORE-FA trial advances, targeting frataxin increase in FA with interim data due this year.

RESTORE-FA and pipeline programs advance toward key data, with funding secured into 2029.

GeneTACⓇ platform advances four programs for genetic diseases, with strong clinical and financial momentum.

Clinical-stage genetic medicine programs in FA, FECD, and DM1 advance toward key data readouts.

Clinical pipeline advanced, net loss $69.8M, cash reserves $219.8M fund operations into 2029.

Advancing gene-targeted therapies with key clinical data expected 2026–2027 and strong cash runway.

Multiple clinical milestones in 2026 and strong cash runway position the pipeline for growth.

GeneTACⓇ platform advances four programs for severe genetic diseases with strong clinical momentum.

Initiating DT-818 clinical trial for DM1 in 2026, with $206M cash and increased Q3 net loss.

GeneTACs show clinical promise in rare genetic diseases, with robust progress and funding.

Q2 2025 saw clinical progress and a $19.1M net loss, with $216.3M cash and ongoing FDA hold risk.

Advancing genomic medicines for FA and FECD with improved safety, efficacy, and strong funding.

Gene tag platform advances with clinical progress in FA and Fuchs' dystrophy, plus new pipeline assets.

Favorable clinical progress and robust cash reserves position Design Therapeutics for future growth.

Gene-targeted therapies advance with new clinical data expected and strong funding into 2029.